ReNeuron Group (AIM:RENE ) announced on Thursday new positive data relating to its CTX cell therapy candidate which has now been published in the scientific journal Stem Cells.
The data was included in a paper entitled “Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease".
The developer of cell-based therapeutics said data showed for the first time that its CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease.
Dr Randolph Corteling, Head of Research at ReNeuron said the data showed “a significant advance” in the potential use of CTX therapy to treat the progressive genetic brain disorder.
The data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and has the ability to generate new brain cells.
Shares in ReNeuron Group were trading 13.48% higher at 160p on Thursday morning.
The group said the results were ‘particularly encouraging’ as they also demonstrate that CTX can differentiate into medium spiny neurons, engraft into host tissue and form functional connections with the surrounding tissue.
ReNeuron believes that the new positive data will add further value to its CTX cell therapy candidate in terms of future out-licensing deals with development partners in due course.
Corteling added that ReNeuron's CTX cell line allows for the scaled production of 'off the shelf' human neural stem cells, with the potential to treat a variety of different neurological disorders.
The company has previously presented data demonstrating that its CTX stem cell line can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.
ReNeuron’s stem cell line is currently undergoing clinical evaluation for the treatment of stroke disability, this morning’s statement outlined.
Follow News & Updates from ReNeuron Group here: